Home > Healthcare > Medical Devices > Diagnostic Devices > tuberculosis diagnostics test market
Get a free sample of Tuberculosis Diagnostics Test Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Tuberculosis Diagnostics Test Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Growing awareness and screening programs for tuberculosis are stimulating the market. Increased public consciousness and proactive screening efforts, led by various organizations, encourage early detection and intervention.
U.S. tuberculosis diagnostics test market accounted for USD 846 million in 2023 and is predicted to witness substantial growth through 2032, favored by the advanced healthcare infrastructure, a robust R&D landscape, and a high prevalence of TB in the region.
The pathological laboratories segment garnered USD 1.20 billion revenue in 2023, attributed to the crucial role in conducting sophisticated diagnostic tests, including Nucleic Acid Amplification Tests (NAATs), molecular assays, and other pathological screening.
The global tuberculosis diagnostics test industry was valued at USD 2.3 billion in 2023 and is estimated to reach USD 3.7 billion by 2032, owing to the rising prevalence of TB.
Abbott Laboratories, Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Siemens Healthineers AG., bioM